Jiangsu Jibeier Pharmaceutical (688566) Q2 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 reached ¥454.92 million, up 4.90% year-over-year; net profit attributable to shareholders was ¥149.32 million, up 22.38%.

• Operating cash flow increased 19.62% year-over-year to ¥156.93 million.

• Main products include Leucogen Tablets, Nitrendipine and Atenolol Tablets, Aceclofenac Enteric-coated Tablets, and others, with Leucogen Tablets maintaining a leading market position.

• R&D pipeline advanced, with key drugs in late-stage clinical trials, including innovative antidepressant and antitumor drugs.

Financial highlights

• Operating income: ¥454.92 million, up 4.90% year-over-year.

• Net profit attributable to shareholders: ¥149.32 million, up 22.38% year-over-year.

• Operating cash flow: ¥156.93 million, up 19.62% year-over-year.

• Basic and diluted EPS: ¥0.75, up 15.38% year-over-year.

• Gross margin: 89.8%.

• R&D investment: ¥34.87 million, representing 7.66% of revenue.

• Dividend proposal: ¥2.60 per 10 shares, total cash dividend ¥51.85 million.

Outlook and guidance

• Continued focus on innovative drug R&D, with several late-stage clinical projects expected to reach key milestones in 2025–2026.

• Ongoing expansion of production and R&D facilities, with significant capital investment in high-end formulation R&D center.

• Management expects further revenue and profit growth driven by new product launches and expanded market coverage.